Skip to main content
SpringerLink
Log in

Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28:1443–52.

    Article  PubMed  Google Scholar 

  2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.

    Article  PubMed  Google Scholar 

  3. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Kitamura M. Italy to fund unapproved use of roche drug to cut costs. In: Bloomberg News. 2014. http://www.bloomberg.com/news/2014-06-10/italy-to-fund-unapproved-use-of-roche-drug-to-cut-costs.html. Accessed 13 Aug 2014.

  5. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417–28.

    Article  PubMed  Google Scholar 

  6. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429–37.

    Article  PubMed  Google Scholar 

  7. Palazzuoli A, Ruocco G, Pellegrini M, et al. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag. 2014;10:641–50.

    Article  PubMed  PubMed Central  Google Scholar 

  8. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–145.

    Article  Google Scholar 

  9. Falck S, Adimadhyam S, Meltzer DO, Walton SM, Galanter WL. A trial of indication based prescribing of antihypertensive medications during computerized order entry to improve problem list documentation. Int J Med Inform. 2013;82:996–1003.

    Article  PubMed  Google Scholar 

  10. Walton SM, Galanter WL, Rosencranz H, et al. A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label. Appl Clin Inform. 2011;2:94–103.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Jackson J. FDAMA 1997 section 114: another look. Value Health. 2009;12:191–2.

    Article  PubMed  Google Scholar 

  12. Neumann PJ. What ever happened to FDAMA section 114? A look back after 10 years. Value Health. 2009;12:189–90.

    Article  PubMed  Google Scholar 

  13. Dennis B. FDA has free-speech, safety issues to weigh in review of ‘off-label’ drug marketing rules. In: The Washington Post. 2014. http://www.washingtonpost.com/national/health-science/2014/07/09/3708dd6a-fbc4-11e3-8176-f2c941cf35f1_story.html. Accessed 13 Aug 2014.

  14. Afzali HH, Karnon J, Merlin T. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making. 2013;33:325–32.

    Article  PubMed  Google Scholar 

  15. Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med. 2012;24:137–46.

    PubMed  Google Scholar 

  16. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150:336–43.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors received no funding related to this editorial and have no conflicts of interest with regard to this topic.

Author information

Authors and Affiliations

  1. Department of Pharmacy Systems, Outcomes, and Policy, UIC, 833 S. Wood Street (M/C 871), Chicago, IL, 60612, USA

    Surrey M. Walton & Glen T. Schumock

Authors
  1. Surrey M. Walton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glen T. Schumock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Surrey M. Walton.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walton, S.M., Schumock, G.T. Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?. PharmacoEconomics 32, 1035–1037 (2014). https://doi.org/10.1007/s40273-014-0222-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-014-0222-2

Search

Navigation